Showing 1531-1540 of 3038 results for "".
- Survey: 80% of Consumers Would Be More Likely To Visit a Doctor if They Could See the Exact Out-of-Pocket Cost On Their Smartphonehttps://modernod.com/news/survey-80-of-consumers-would-be-more-likely-to-visit-a-doctor-if-they-could-see-the-exact-out-of-pocket-cost-on-their-smartphone/2476190/Metova, a provider of mobile, connected car, connected home and IoT Solutions, announced findings from a “Mobile First” survey on health care and technology, revealing the sentiment of over 1,000 consumers who currently have health care. The survey was conducted to research the growin
- CooperVision Specialty EyeCare Launches New Mobile Application for Paragon CRT and Dual Axis Contact Lens Fittinghttps://modernod.com/news/coopervision-specialty-eyecare-launches-new-mobile-application-for-paragon-crt-and-dual-axis-contact-lens-fitting/2480314/CooperVision Specialty EyeCare launched its innovative Paragon CRT Calculator mobile application for eye care professionals (ECPs). The multifunctional app includes several features aimed at simplifying the fitting process for CRT and CRT
- Lumenis Unveils Its First US Tour With Launch Of Mobile Outdoor Tradeshow Boothhttps://modernod.com/news/lumenis-unveils-its-first-us-tour-with-launch-of-mobile-outdoor-tradeshow-booth/2478311/Lumenis has announced its first mobile tour (LuMobile), September 28 through April 2021. The company will bring its flagship devices to practitioners in a safe environment aboard the new LuMobile outdoor tradeshow exhibit. The 20-city mo
- RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye Care Providershttps://modernod.com/news/retina-ai-releases-the-first-artificial-intelligence-mobile-app-for-eye-care-providers/2480018/RETINA-AI has developed and released the first artificial intelligence mobile app for eye care providers. The app, called Fluid Intelligence by RETINA-AI, detects macular edema and subretinal fluid on OCT retinal scans with greater than 90% accuracy, according to a company news release. Fl
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/Lytenava (Bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-reports-final-visit-for-last-patient-in-open-label-safety-study-for-ons-5010-lytenava-bevacizumab-vikg/2478861/Outlook Therapeutics announced that the last patient completed their final visit for the ongoing open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases (NORSE THREE). Two of the three planned clinical trials for the ONS-5010/Lytenava wet age
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- The Vision Council Announces Dates for the 2021 Virtual Executive Summit: January 26–28, 2021https://modernod.com/news/the-vision-council-announces-dates-for-the-2021-virtual-executive-summit-january-26-28-2021/2478440/The Vision Council today announces that the
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- NIH Mobilizes National Innovation Initiative For COVID-19 Diagnosticshttps://modernod.com/news/nih-mobilizes-national-innovation-initiative-for-covid-19-diagnostics/2477698/The National Institutes of Health (NIH) announced a new initiative aimed at speeding innovation, development, and commercialization of COVID-19 testing technologies. With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) in